Tolerance in clinical liver transplantation

Josh Levitsky*, Sandy Feng

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

While advances in immunosuppressive therapy have lowered the rate of acute rejection following liver transplantation, the consequence has been an increase in morbidity and mortality related to the lifelong need for maintenance immunosuppression. These complications include an increased risk of malignancy, infection, metabolic disorders, and chronic kidney disease, as well as high health care costs associated with these therapies and the required drug monitoring. Given these issues, most clinicians attempt trial and error dose minimization with variable success rates, and there has been significant interest in full drug withdrawal in select patients through research protocols. These strategies would be more successful if immunomodulatory therapies early after transplantation could be developed and if immune activation biomarkers guiding drug tapering were available to personalize these approaches. This review will review the mechanisms of liver transplant tolerance and potential strategies to achieve immunosuppression withdrawal.

Original languageEnglish (US)
Pages (from-to)283-287
Number of pages5
JournalHuman Immunology
Volume79
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Liver Transplantation
Immunosuppression
Immunomodulation
Drug Monitoring
Immunosuppressive Agents
Chronic Renal Insufficiency
Pharmaceutical Preparations
Health Care Costs
Transplantation
Biomarkers
Maintenance
Morbidity
Transplants
Mortality
Liver
Therapeutics
Infection
Research
Neoplasms

Keywords

  • Biomarkers
  • Immunosuppression
  • Regulatory T cells
  • Rejection
  • Withdrawal

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Levitsky, Josh ; Feng, Sandy. / Tolerance in clinical liver transplantation. In: Human Immunology. 2018 ; Vol. 79, No. 5. pp. 283-287.
@article{1a3387b0611f4f74b6b37c7822447b03,
title = "Tolerance in clinical liver transplantation",
abstract = "While advances in immunosuppressive therapy have lowered the rate of acute rejection following liver transplantation, the consequence has been an increase in morbidity and mortality related to the lifelong need for maintenance immunosuppression. These complications include an increased risk of malignancy, infection, metabolic disorders, and chronic kidney disease, as well as high health care costs associated with these therapies and the required drug monitoring. Given these issues, most clinicians attempt trial and error dose minimization with variable success rates, and there has been significant interest in full drug withdrawal in select patients through research protocols. These strategies would be more successful if immunomodulatory therapies early after transplantation could be developed and if immune activation biomarkers guiding drug tapering were available to personalize these approaches. This review will review the mechanisms of liver transplant tolerance and potential strategies to achieve immunosuppression withdrawal.",
keywords = "Biomarkers, Immunosuppression, Regulatory T cells, Rejection, Withdrawal",
author = "Josh Levitsky and Sandy Feng",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.humimm.2017.10.007",
language = "English (US)",
volume = "79",
pages = "283--287",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "5",

}

Tolerance in clinical liver transplantation. / Levitsky, Josh; Feng, Sandy.

In: Human Immunology, Vol. 79, No. 5, 01.05.2018, p. 283-287.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Tolerance in clinical liver transplantation

AU - Levitsky, Josh

AU - Feng, Sandy

PY - 2018/5/1

Y1 - 2018/5/1

N2 - While advances in immunosuppressive therapy have lowered the rate of acute rejection following liver transplantation, the consequence has been an increase in morbidity and mortality related to the lifelong need for maintenance immunosuppression. These complications include an increased risk of malignancy, infection, metabolic disorders, and chronic kidney disease, as well as high health care costs associated with these therapies and the required drug monitoring. Given these issues, most clinicians attempt trial and error dose minimization with variable success rates, and there has been significant interest in full drug withdrawal in select patients through research protocols. These strategies would be more successful if immunomodulatory therapies early after transplantation could be developed and if immune activation biomarkers guiding drug tapering were available to personalize these approaches. This review will review the mechanisms of liver transplant tolerance and potential strategies to achieve immunosuppression withdrawal.

AB - While advances in immunosuppressive therapy have lowered the rate of acute rejection following liver transplantation, the consequence has been an increase in morbidity and mortality related to the lifelong need for maintenance immunosuppression. These complications include an increased risk of malignancy, infection, metabolic disorders, and chronic kidney disease, as well as high health care costs associated with these therapies and the required drug monitoring. Given these issues, most clinicians attempt trial and error dose minimization with variable success rates, and there has been significant interest in full drug withdrawal in select patients through research protocols. These strategies would be more successful if immunomodulatory therapies early after transplantation could be developed and if immune activation biomarkers guiding drug tapering were available to personalize these approaches. This review will review the mechanisms of liver transplant tolerance and potential strategies to achieve immunosuppression withdrawal.

KW - Biomarkers

KW - Immunosuppression

KW - Regulatory T cells

KW - Rejection

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=85032230673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032230673&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2017.10.007

DO - 10.1016/j.humimm.2017.10.007

M3 - Review article

C2 - 29054397

AN - SCOPUS:85032230673

VL - 79

SP - 283

EP - 287

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 5

ER -